Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

[1]  J. Stockman.  A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease , 2013 .

[2]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[3]  N. LaRusso,et al.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  R. Miniero,et al.  Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglobin Concentration in Children With Idiopathic Growth Hormone Deficiency-related Anemia , 2012, Journal of pediatric hematology/oncology.

[5]  V. Torri,et al.  Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly , 2012, PloS one.

[6]  N. Perico,et al.  Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study , 2012, PloS one.

[7]  J. Stockman,et al.  Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease , 2012 .

[8]  R. Schrier,et al.  Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[9]  J. Glockner,et al.  Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. , 2011, Kidney international.

[10]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[11]  Oliver Senn,et al.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. , 2010, The New England journal of medicine.

[12]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[13]  L. Antiga,et al.  Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[14]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[15]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[16]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[17]  J. Grantham,et al.  Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.

[18]  N. LaRusso,et al.  Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.

[19]  A. Chapman,et al.  Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[20]  L. Antiga,et al.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.

[21]  J. Grantham,et al.  Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. , 2003, Kidney international.

[22]  Vincent H Gattone,et al.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.

[23]  Paul A Thompson,et al.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. , 2003, Kidney international.

[24]  F. Petraglia,et al.  Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. , 2001, Fertility and sterility.

[25]  G. Remuzzi,et al.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.

[26]  D. Wallace,et al.  Chloride and fluid secretion in polycystic kidney disease. , 1998, Journal of the American Society of Nephrology : JASN.

[27]  J. Grantham,et al.  Mechanisms of progression in autosomal dominant polycystic kidney disease. , 1997, Kidney international. Supplement.

[28]  J. Edwardson,et al.  Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization , 1997, British journal of pharmacology.

[29]  N. Perico,et al.  Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. , 1995, Journal of the American Society of Nephrology : JASN.

[30]  R. G. Walker,et al.  Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 , 1994, The Lancet.

[31]  U. Studer,et al.  Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. , 1993, The Journal of clinical endocrinology and metabolism.

[32]  W. Jiménez,et al.  Effects of somatostatin on renal function in cirrhosis. , 1992, Gastroenterology.

[33]  C. Sullivan,et al.  Effects of long term octreotide on gall stone formation and gall bladder function. , 1992, BMJ.

[34]  T. M. Hayes,et al.  Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. , 1987, The Journal of clinical endocrinology and metabolism.

[35]  L. Travis,et al.  Somatostatin limits rise in glomerular filtration rate after a protein meal. , 1987, The Journal of pediatrics.

[36]  B. Brenner,et al.  Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. , 1985, The Journal of clinical investigation.